Background
Methods
Patients and study design
Definitions
Laboratory testing
Statistical analysis
Results
Patient characteristics
Characteristic | Total (n = 334, %) | Nosocomial SBP (n = 155, %) | Community-acquired SBP (n = 179, %) | P value |
---|---|---|---|---|
Age, mean years ± SD | 55.5 ± 10.4 | 56.3 ± 10.3 | 54.9 ± 10.4 | 0.222 |
Sex, Male | 270 (80.8) | 127 (81.9) | 143 (79.9) | 0.635 |
Main cause of liver cirrhosis (n, %) | 0.903 | |||
HBV infection | 145 (43.4) | 67 (43.2) | 78 (43.6) | 0.949 |
HCV infection | 31 (9.3) | 17 (11.0) | 14 (7.8) | 0.323 |
Alcohol use | 123 (36.8) | 55 (35.5) | 68 (38.0) | 0.636 |
Primary biliary cirrhosis | 15 (4.5) | 7 (4.5) | 8 (4.5) | 0.984 |
Other | 20 (6.0) | 9 (5.8) | 11 (6.1) | 0.896 |
Child-Pugh classification | 0.453 | |||
Class B | 82 (24.6) | 41 (26.5) | 41 (22.9) | |
Class C | 252 (75.4) | 114 (73.5) | 138 (77.1) | |
MELD score ± SD | 16.9 ± 9.7 | 17.6 ± 10.0 | 16.0 ± 9.4 | 0.218 |
Initial presenting symptoms | ||||
Fever | 178 (53.3) | 107 (69.0) | 71 (39.7) | < 0.001 |
Vomiting/diarrhea | 57 (17.1) | 30 (19.4) | 27 (15.1) | 0.301 |
Abdominal pain | 153 (45.8) | 81 (52.3) | 72 (40.2) | 0.028 |
Hepatic encephalopathy | 69 (20.7) | 38 (24.5) | 31 (17.3) | 0.105 |
Gastrointestinal bleeding | 38 (11.4) | 18 (11.6) | 20 (11.2) | 0.900 |
Renal failure | 65 (19.5) | 40 (25.8) | 25 (14.0) | 0.006 |
Septic shock | 25 (7.5) | 13 (8.4) | 12 (6.7) | 0.560 |
Hepatocellular carcinoma | 93 (28.7) | 55 (35.5) | 38 (21.2) | 0.004 |
Microbiological characteristics
Pathogen | No. (%) of patients | p value | ||
---|---|---|---|---|
Total (n = 334, %) | Nosocomial SBP (n = 155, %) | Community-acquired SBP (n = 179, %) | ||
Gram-negative bacteria | 178 (53.3) | 75 (48.4) | 103 (57.5) | 0.094 |
Escherichia coli
| 81 (24.3) | 32 (20.6) | 49 (27.4) | 0.152 |
Klebsiella pneumoniae
| 40 (12.0) | 14 (9.0) | 26 (14.5) | 0.123 |
Acinetobacter spp.
| 11 (3.3) | 6 (3.9) | 5 (2.8) | 0.582 |
Enterobacter cloacae
| 7 (2.1) | 3 (1.9) | 4 (2.2) | 0.849 |
Enterobacter species
| 19 (5.7) | 8 (5.2) | 11 (6.1) | 0.699 |
Pseudomonas aeruginosa
| 7 (2.1) | 3 (1.9) | 4 (2.2) | 0.849 |
Aeromonas species
| 4 (1.2) | 1 (0.6) | 3 (1.7) | 0.719 |
Sphingomonas paucimobilis
| 1 (0.3) | 1 (0.6) | 0 (0.0) | 0.464 |
Salmonella
| 1 (0.3) | 0 (0.0) | 1 (0.6) | NS |
Stenotrophomonas maltophilia
| 7 (2.1) | 7 (4.5) | 0 (0.0) | 0.004 |
Gram-positive bacteria | 138 (41.3) | 73 (47.1) | 65 (36.3) | 0.046 |
Streptococcus pneumoniae
| 6 (1.8) | 1 (0.6) | 5 (2.8) | 0.289 |
Streptococcus (other than S. pneumoniae)
| 26 (7.8) | 8 (5.2) | 18 (10.1) | 0.096 |
Enterococcus faecalis
| 16 (4.8) | 14 (9.0) | 2 (1.1) | 0.002 |
Enterococcus faecium
| 35 (10.5) | 28 (18.1) | 7 (3.9) | < 0.001 |
Other Enterococcus
| 3 (0.9) | 1 (0.6) | 2 (1.1) | NS |
Staphylococcus aureus
| 16 (4.8) | 9 (5.8) | 7 (3.9) | 0.418 |
Coagulase-negative staphylococci
| 31 (9.3) | 12 (7.7) | 19 (10.6) | 0.376 |
Listeria monocytogenes
| 5 (1.5) | 0 (0.0) | 5 (2.8) | 0.064 |
Fungi | 14 (4.2) | 6 (4.5) | 8 (3.9) | 0.786 |
Candida albicans
| 7 (2.1) | 3 (2.6) | 4 (1.7) | |
Candida glabrata
| 3 (0.9) | 1 (0.6) | 2 (1.1) | |
Candida tropicalis
| 2 (0.6) | 1 (0.6) | 1 (0.6) | |
Candida parapsilosis
| 1 (0.3) | 1 (0.6) | 0 (0.0) | |
Cryptococcus neoformans
| 1 (0.3) | 0 (0.0) | 1 (0.6) | |
Anaerobe | 4 (1.2) | 1 (0.6) | 3 (1.7) | 0.627 |
Antibiotics | Escherichia coli (n = 81) | Klebsiella pneumoniae (n = 40) | ||||
---|---|---|---|---|---|---|
Nosocomial (n = 32) | Community-acquired (n = 49) |
p value
| Nosocomial (n = 14) | Community-acquired (n = 26) |
p value
| |
ESBL | 25 (78.1) | 15 (30.6) | 0.000 | 4 (28.6) | 2 (7.7) | 0.194 |
Ampicillin | 29 (90.6) | 43 (87.8) | 0.968 | 14 (100) | 24 (92.3) | 0.533 |
Piperacillin | 28 (87.5) | 37 (75.5) | 0.299 | 6 (42.9) | 3 (11.5) | 0.062 |
Amoxicillin-clavulanic acid | 12 (37.5) | 10 (20.4) | 0.091 | 3 (21.4) | 1 (3.8) | 0.224 |
Piperacillin/tazobactam | 4 (12.5) | 0 | 0.022 | 2 (14.3) | 0 | 0.117 |
Cefazolin | 26 (81.2) | 13 (26.5) | 0.000 | 4 (28.6) | 4 (15.4) | 0.562 |
Ceftazidime | 25 (78.1) | 13 (26.5) | 0.000 | 4 (28.6) | 2 (7.7) | 0.194 |
Cefotaxime | 27 (84.3) | 15 (30.6) | 0.000 | 4 (28.6) | 2 (7.7) | 0.194 |
Cefepime | 23 (71.9) | 11 (22.4) | 0.000 | 4 (28.6) | 0 | 0.011 |
Aztreonam | 18 (56.3) | 10 (20.4) | 0.001 | 2 (14.3) | 1 (3.8) | 0.571 |
Imipenem | 2 (6.3) | 0 | 0.153 | 2 (14.3) | 0 | 0.117 |
Meropenem | 1 (3.1) | 0 | 0.395 | 1 (7.1) | 0 | 0.350 |
Amikacin | 2 (6.3) | 0 | 0.153 | 1 (7.1) | 0 | 0.350 |
Levofloxacin | 23 (71.9) | 21 (42.9) | 0.01 | 3 (21.4) | 1 (3.8) | 0.224 |
SMZ | 21 (65.6) | 30 (61.2) | 0.688 | 3 (21.4) | 4 (15.4) | 0.965 |
Gentamicin | 17 (53.1) | 25 (51.0) | 0.853 | 2 (14.3) | 2 (7.7) | 0.912 |
Tetracycline | 25 (78.1) | 39 (79.6) | 0.874 | 4 (28.6) | 4 (15.4) | 0.562 |
Antibiotics | Staphylococcus aureus (n = 16) | Enterococcus (n = 54) | ||||
---|---|---|---|---|---|---|
Nosocomial (n = 9) | Community-acquired (n = 7) |
p value
| Nosocomial (n = 43) | Community-acquired (n = 11) |
p value
| |
Penicillin | 8 (88.9) | 5 (71.4) | 0.550 | 37 (86.0) | 8 (72.7) | 0.546 |
Oxacillin | 6 (66.7) | 3 (42.9) | 0.615 | – | – | – |
Erythromycin | 8 (88.9) | 4 (57.1) | 0.262 | 36 (83.7) | 6 (54.5) | 0.038 |
Clindamycin | 7 (77.8) | 1 (14.3) | 0.041 | – | – | – |
Nitrofurantoin | 0 | 0 | NS | 25 (58.1) | 2 (18.2) | 0.043 |
Rifampicin | 0 | 0 | NS | 37 (86.0) | 8 (72.7) | 0.546 |
Tetracycline | 4 (44.4) | 2 (28.6) | 0.633 | 24 (55.8) | 6 (54.5) | 0.940 |
Ciprofloxacin | 5 (55.6) | 2 (28.6) | 0.358 | 32 (74.4) | 8 (72.7) | 0.909 |
SMZ | 1 (11.1) | 1 (14.3) | NS | – | – | – |
Linezolid | 0 | 0 | NS | 0 | 0 | NS |
Vancomycin | 0 | 0 | NS | 8 (18.6) | 1 (9.1) | 0.762 |
Teicoplanin | 0 | 0 | NS | 4 (9.3) | 0 | 0.571 |
Clinical outcome and predictors of mortality
Risk factor | Survivors (n = 233) | Nonsurvivors (n = 101) | Univariate | Multivariate | ||
---|---|---|---|---|---|---|
P value | p value | HR | 95% CI | |||
Age, mean years _ SD | 55.3 ± 10.7 | 56.1 ± 9.9 | 0.869 | – | – | – |
Male | 191 | 79 | 0.401 | – | – | – |
Child-Pugh classification | 0.007 | 0.007 | 2.167 | 1.236–3.798 | ||
Class B | 67 | 15 | ||||
Class C | 166 | 86 | ||||
Hepatocellular carcinoma | 53 | 40 | 0.005 | 0.002 | 1.930 | 1.284–2.901 |
Nosocomial infection | 98 | 57 | 0.005 | 0.044 | 1.514 | 1.012–2.267 |
Resistance to third - generation cephalosporins | 77 | 40 | 0.321 | – | – | – |
Gastrointestinal bleeding | 23 | 15 | 0.105 | – | – | – |
Renal failure | 34 | 31 | 0.001 | < 0.001 | 2.244 | 1.440–3.496 |
Septic shock | 14 | 11 | 0.156 | – | – | – |
Hepatic encephalopathy | 37 | 32 | < 0.001 | 0.012 | 1.739 | 1.129–2.677 |